Arrowhead Pharmaceuticals (ARWR) FY2018 results: revenue $16 million, down 48.6% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $16 million for fiscal 2018, the year ended 30 September 2018, down 48.6% on the year before. Net income was -$54 million, and diluted earnings per share $-0.65. The figures are the company's own, from the 10-K it filed with the SEC on 11 December 2018.
Revenue
$16 million
-48.6% on the year
FY2011FY2018
Operating margin
-346.5%
-117.8% a year earlier
FY2011FY2018
Net income
-$54 million
FY2011FY2018
Diluted EPS
-$0.65
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
16.1
31.4
0.2
-48.6%
Research and development
53.0
50.9
62.1
+4.1%
Operating income
-55.9
-37.0
-81.7
Operating margin
-346.5%
-117.8%
-51627.1%
Pre-tax income
-54.4
-34.4
-81.7
Income tax
0.0
0.0
0.0
0.0%
Net income
-54.5
-34.4
-81.7
Net margin
-337.3%
-109.5%
-51614.6%
Diluted EPS
-$0.65
-$0.47
-$1.34
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
-47.2
-23.9
-64.4
Capital expenditure
1.4
7.9
3.9
-82.1%
Free cash flow
-48.6
-31.9
-68.3
Free cash flow margin
-301.3%
-101.4%
-43129.2%
Cash from investing
-7.4
-48.6
13.4
Cash from financing
60.0
12.1
55.1
+397.3%
Depreciation and amortisation
3.0
3.0
3.3
+0.3%
Share-based compensation
8.5
7.9
11.6
+7.1%
Diluted shares, weighted
84m
74m
n/a
+13.2%
Shares outstanding at period end
89m
75m
70m
+18.3%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
95.8
81.4
95.6
+17.7%
Non-controlling interest
-0.6
-0.6
-0.6
Debt
2.1
2.3
2.5
-9.6%
Other liabilities
14.3
20.8
30.6
-31.5%
Total liabilities and equity
112
104
128
+7.3%
Fixed assets
13.9
15.5
15.4
-10.2%
Intangible assets
18.8
20.5
22.2
-8.3%
Securities held for sale or to maturity
46.4
40.8
n/a
+13.8%
Cash and equivalents
30.1
24.8
85.4
+21.3%
Receivables
0.3
0.1
0.1
+382.9%
Other assets
2.0
2.4
5.2
-13.5%
Total assets
112
104
128
+7.3%
10-K for the year ended 30 September 2018, filed 11 December 2018: the filing.